ABS 102
Alternative Names: ABS-102Latest Information Update: 11 Oct 2022
Price :
$50 *
At a glance
- Originator Amberstone Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 19 Sep 2022 ABS 102 is available for licensing as of 19 Sep 2022. https://amberstonebio.com/technology/
- 19 Sep 2022 Amberstone Biosciences files for patent protection for microfluidic systems and its methods and systems for performing assays in multiple countries worldwide ,,,
- 19 Sep 2022 Early research in Solid tumours in USA (Parenteral) (Amberstone Biosciences website, September 2022)